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The Role of Non-ras Transforming Genes in
Chemical Carcinogenesis
by Colin S. Cooper*
DNA transfection experiments using the NIH 3T3 mouse fibroblast cell line have demonstrated that
chemically induced tumors and chemically transformed cell lines frequently contain dominant transform-
ing genes. Although many ofthe genes detected using the NIH 3T3 transfection-transformation assay are
activated versions ofH-ras, K-ras, and N-ras, in some experimental systems activated forms ofgenes such
as metand neu that are unrelated to ras have been observed. The activated metgene wasoriginallydetected
in a human cell line that had been transformed by exposure to N-methyl-N'-nitro-N-nitrosoguanidine.
Subsequent studies demonstrated that the met proto-oncogene encodes a novel growth factor receptor and
that gene activation involves the production of a chimeric gene in which the regions of met encoding the
extracellular and transmembrane domains of the receptor are replaced by the 5'-region of an unrelated
gene called trp. The activated neu gene was detected in tumors of the nervous system that arose in mice
following transplacental exposure to N-ethyl-N-nitrosourea. The neu gene also encodes a novel growth
factor receptor but, in contrast to met, its activation involves a single T:A -* A:T point mutation in the
region of the neu gene encoding the receptor transmembrane domain.
The presence of genetic alterations in chemically induced malignancies has also been assessed in cy-
togenetic studies and by Southern analysis ofDNA from neoplastic cells. These studies have demonstrated
the presence of altered versions the c-myc and mos genes in plasmocytomas induced in mice following
exposure to pristane or mineral oil and ofactivatedpim-1 and c-myc genes in thymomas that arise in AKR
mice following treatment withN-methyl-N-nitrosourea. Analyses ofthe mechanisms ofactivation ofthese
non-ras genes hasprovided important insights intothe different ways in which genes may become activated
following chemical exposure.
Introduction
The new technologies of DNA transfections and mo-
lecular biology have resulted in major advances in our
understanding ofthe molecular mechanisms ofchemical
carcinogenesis. Indirect support for the idea that DNA
is the critical target during chemical carcinogenesis was
originally provided a) by the discovery, for particular
classes ofchemical carcinogens, ofcorrelations between
carcinogenicity and the extents of covalent binding to
DNAintargettissue; b)bythediscovery ofcorrelations
betweencarcinogenicity andmutagenicity; andc)bythe
identification of karyotypic abnormalities in cells from
chemically induced malignancies (1-5).
The first direct support for the concept that chemical
transformation may involve the generation ofactivated
transforming genes (oncogenes) by alteration ofnormal
cellular genes (proto-oncogenes) was, however, pro-
vided by the observation that DNA from lines ofchem-
ically transformed cells could be used to transform a
line ofNIH 3T3 mouse fibroblasts in DNA transfection
experiments (6). The DNA transfection procedure and
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other techniques that can now be used for detecting
activated cellular genes have been applied to at least a
dozen model systems oftumor induction and cell trans-
formation, and it has become apparent that the identity
of the activated gene detected using these procedures
depends upon the experimental system under investi-
gation.
In many studies, all ofthe genes detected are mem-
bers ofthe ras gene family (H-,K-, and N-ras) that are
usually activated by point mutations in codons 12 or 61.
For example, H-ras is activated in N-methyl-N-nitro-
sourea (MNU)-induced rat mammary tumors and in di-
methylbenz[a]anthracene (DMBA)-initiated mouse skin
papillomas and carcinomas, while both N-ras and K-ras
are activated in thymomas that arise in MNU-treated
RF/AKR mice (7-12). However, genes that are unre-
lated to ras are also frequently detected, and in a mi-
nority of cases (e.g., for met and neu), the mechanism
of gene activation of these non-ras genes has been ex-
amined in detail (13-16). Since the role of ras gene
activation in chemical carcinogenesis has been ade-
quately discussed elsewhere (17-19), this review will
deal entirely with the non-ras genes that are activated
in chemically induced tumors and chemically trans-
formed cell lines.C. S. COOPER
The met Gene
The met gene was originally detected by transfection
of DNA from a transformed human cell line, called
MNNG-HOS (20,21), that was derived bytreating HOS
cells with N-methyl-N'-nitro-N-nitrosoguanidine
(MNNG). The HOS cell line is, as its name implies,
derived from a human osteosarcoma. HOS cells exhibit
a flat morphology when grown in tissue culture and do
not induce tumors when injected into nude mice. They
can, however, be converted into morphologically trans-
formed cells that form tumors when injected into nude
mice by treatment with chemical carcinogens, such as
MNNG and DMBA (22, 23). In DNA transfection ex-
periments, the activated met gene was detected in
MNNG-HOS cells but not in the parent HOS cell line,
indicating that treatment ofHOS cells with MNNG had
given rise to a dominant transforming gene (20).
The DNA sequence of cDNA clones prepared from
transcripts ofthe met proto-oncogene revealed that the
normal cellular mouse met genes encode a 1380 amino
acid protein with the characteristics of a growth factor
receptor (24) (Fig. 1). The N-terminal 18 amino acids
of this protein is rich in hydrophobic residues, sug-
gestingthat this region ofthe protein is a signal peptide
used for insertion into the membrane. A second hydro-
phobic domain is found at residues 930 to 954. This
domain has the characteristics of a membrane-spanning
region and is followed by a highly basic stretch of res-
idues that may function as a "stop transfer" sequence.
The putative transmembrane domain divides the met
protein into two regions that correspond to the extra-
cellular and intracellular-portions of the protein. The
amino-terminal extracellular domain of 929 amino acids
contains many cysteine domains, including a small cys-
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FIGURE 1. Diagram comparing the structures of epidermal growth
factorreceptor(HER, class Ireceptor), the insulinreceptor(HIR,
class II receptor), the platelet-derived growth factor receptor
(PDGF-R, class III receptor) and the metreceptorprotein (MET).
The tyrosine kinase domain (l 1), cysteine residues (O), and
cysteine-rich regions () are shown. The neu protein has a
structure similar to that shown for the epidermal growth factor
receptor.
teine-rich region, and 10 consensus sequences for as-
paragine-linked N-glycosylation (Asn-Xaa-Ser/Thr).
The cytoplasmic domain of 426 amino acids contains a
protein tyrosine kinase (PTK) region that has a unique
domain of 127 amino acids between the transmembrane
and PTK domains that is much longer than the corre-
sponding domains found in other tyrosine kinase recep-
tors (24) (Fig. 1). The human met protein has an almost
identical structure (25).
Examination of the predicted amino acid sequences
of the mouse met protein revealed the presence of a
potential proteolytic cleavage site with the sequences
Lys-Arg-Arg-Lys-Arg-Ser 302 amino acids from the
amino terminals (24). This basic sequence is similar to
the sequence Arg-Lys-Arg-Arg-Ser found at the cleav-
age site of the insulin receptor precursor and to the
sequence Arg-Lys-Arg-Arg-Asp found at the cleavage
site of the precursor of the insulinlike growth factor I
receptor (26,27). In the precursors of the insulin and
insulinlike growth factor I receptors, this is the site for
cleavage ofthe precursor into a and 1B subunits, which
in the mature receptor are joined by disulfide bonds in
ana2132configuration (Fig. 1) (28). Cleavage atthebasic
sequence present in the met protein and removal ofthe
signal peptide would generate and N-terminal peptide
of 282 amino acids that might become associated with
the remaining membrane-bound portion ofthe met pro-
tein in a manner similar to that observed for the insulin
and insulinlike growth factor I receptors (24,29).
To test this hypothesis, the structure ofthe met pro-
tein was examined directly using antibodies raised
against synthetic peptide corresponding to the carboxy
terminus of the met protein. When proteins were ex-
tracted, immunoprecipitated, and subjected to gel elec-
trophoresis under nonreducing conditions, a 190-kDa
protein was observed. However, when this 190-kDa
protein was excised from the gel and treated with 1-
mercaptoethanol, it yielded subunits of 145 kDa and 50
kDa. These results demonstrate that the met protein is
indeed a heterodimer in which a 145-kDa 3-subunit is
joined by disulfide bonds to a 50-kDa a-subunit (29-31)
(Fig. 1).
The biosynthesis of the met protein has been exam-
ined in detail (31). Following metabolic labeling ofcells
in the presence oftunicamycin, an inhibitor ofco-trans-
lational N-glycosylation, anti-met antibodies immuno-
precipitated a protein of 150 kDa; the molecular weight
ofthis protein is an agreement with the size ofthe met
protein calculated from its protein sequence.
Inpulse-chase experiments carried outinthe absence
of tunicamycin, a protein with an apparent molecular
weight of 170 kDa appears first. This early precursor
is already glycosylated but probably does not function
as an active receptor since it is not expressed at the cell
surface nor phosphorylated on tyrosine. The 170-kDa
protein appears to rapidly undergo a conformational
change, probably as a consequence of modification of
intra-chain disulfide bands, to form a protein species
with an apparent molecular weight of 180 kDa. Sub-
sequently, this single polypeptide precursor is cleaved
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toform the 145-kDa ,3-subunit. Although it has not been
unequivocably demonstrated, it is believed that this
precursor also gives rise to the 50-kDa ot subunit. In
the mature receptor, the 1 subunit may be phospho-
rylated on tyrosine, serine, and threonine. The at and
subunits are both detected when cells are labeled with
25I under nonpermeating conditions and are therefore
both exposed at the cell surface (31).
Growth factorreceptors possessing aproteintyrosine
kinase domain are currently classified into different
groups on the basis of common structural motifs (Fig.
1). Receptors belonging to class I (epidermal growth
factor [EGF] receptor and neu) are monomeric and are
characterized by the presence of two cysteine-rich re-
gions within the extracellular domain. Class II induces
the insulin and insulinlike growth factor I receptors,
which have a tetrameric (a2132) subunit structure, while
class III receptors (colony-stimulating factor [CSF]-I
and platelet-derived growth factor [PDGF] receptors)
are monomeric but have a split tyrosine kinase domain.
The met protein seems to be the prototype of a new
class ofreceptors that have a unique ac, subunit struc-
ture. The ligand that is presumed to bind to the met
receptor has not been identified, and represents a pri-
mary goal of future studies must be to identify this
ligand.
Activation of the met gene in MNNG-HOS cells in-
volves a chromosomal rearrangement in which the re-
gion of the met gene encoding the extracellular and
transmembrane domains is replaced by 5' region of an
unrelated gene designated trp (translocated promoter
region) (13,14). This chimeric geneistranscribed topro-
duce a unique 5.0-kb hybrid tpr-met mRNA that is in
turn translated to form a 60- to 65-kDa fusion protein
in which the protein tyrosine kinase domain of met is
fused to the amino-terminal region of the trp protein
(13,14,29,33). The region of the trp protein present in
the trp-met fusion protein exhibits weaker homology to
several structural proteins, including lamininandlamin,
indicating that the normal trp protein may also encode
astructural protein (32). Although theidentity and sub-
cellular location of the normal product of the trp gene
have not been determined, it is possible that formation
ofthe fusion protein may confer transforming potential
in the met protein tyrosine kinase (PTK) domain by
redirecting its subcellular location, thus altering the
spectrum of proteins phosphorylated by the kinase. In
addition, the modification of the structure of met may
alteritsresponsetonormalcellularcontrolmechanisms.
The mechanism ofactivation ofmet is reminiscent of
that observed for the trk and abl genes. Activation of
c-abl occurs in chronic myelogenous leukemia, where
thePhiladelphiatranslocationresultsinthesubstitution
of the 5' sequences at the c-abl gene with bcr gene
sequences. The protein encoded by the activated gene
retains the PTK domain and exhibits enhanced PTK
activitywhencompared tothenormalc-ablprotein(34).
Similarly, during activation of the trk gene, the car-
boxyl-terminal tyrosine kinase domain of a putative
transmembrane receptorbecameattached tothe amino-
terminal221 aminoacidsofnonmuscletropomyosin(35).
Thus, in each case, the 3'-end of the activated gene
encodes a PTK domain, while initiation oftranscription
occurs in a separate DNA domain that comprises the
5'-end ofthe gene.
The neu Gene
A high proportion of offspring of pregnant rats that
have been treated with a single dose of N-ethyl-N-ni-
trosourea (ENU) during the second half of gestation
develop central and peripheral nervous system tumors
after a latency of around 200 days (36-38). Shih et al.
(39) demonstrated that DNA from cell lines derived
from intracranial tumors induced in BD-IX rats could
transform NIH 3T3 cells in the DNA transfection as-
says. The transforming gene transferred in these ex-
periments was unrelated toras and was associated with
the expression ofaphosphoprotein ofrelativemolecular
mass 185,000 (p185) (40). Subsequent studies demon-
strated that neu was related to, but distinct from, the
gene that encodes the EGF receptor (41,42). The nu-
cleotide sequence of the neu cDNA revealed a 1260
amino acid protein that exhibits 50% amino acid ho-
mology to the EGF receptor and possesses the char-
acteristics of a growth factor receptor, including the
presence of a extracellular ligand-binding domain, a
transmembrane domain, and a cytoplasmic protein tyro-
sine kinase domain (43). When considered together,
these observations strongly suggest that neu encodes
a growth factor receptor, although the identity of the
ligand that binds to this putative receptor remains to
be determined.
The cell lines examined by Shih et al. (39) were be-
lieved to be derived from neuroblastomas and glioblas-
tomas that arose in the central nervous system. How-
ever, the identification of these tumors was equivocal
because no histological examination of the primary tu-
mors' tissue was reported and because schwannomas
may also develop intracranially. Indeed, an extensive
study of oncogene activation in primary glial tumors
andschwannomas thatdevelopedintransplacentally ex-
posed F344 rats revealed that neu activation occurred
exclusively in schwannomas; of 59 gliomas examined,
none showed neu gene activation (38).
Comparisons ofthe activated and normal versions of
the neu gene have demonstrated that neu gene acti-
vation in the cell lines derived from intracranial tumors
and in primary schwannomas invariably involves a T:A
--> A:T transversion mutation in codon 664 (15,38). Un-
expectedly, this alteration, which changes valine to glu-
tamic acid, falls within the putative transmembrane do-
main. The presence of this acidic residue in the
otherwisehydrophobictransmembrane domaindoesnot
alter the subcellular location of neu because, like its
normal counterpart, the activated neu protein is mem-
brane associated (44). In addition, the membrane-as-
sociated p185 appears to be responsible for transfor-
mation because antisera to p185 suppress the
transformed phenotype in neu-transformed cells (45).
35C. S. COOPER
In fact, it is now believed that the presence ofthe glu-
tamic acid residue causes activation ofthe receptor by
promoting deimerization and higher PTKactivityinthe
absence ofthe ligand (46).
Although reactions of ENU with target tissue inflict
many different t6ypes of damage on cellular DNA, O6-
ethylguanine (0 -EtG) and 0 -ethylthymine (04-EtT)
are considered to be the major promutagenic lesions.
06-EtG and 04-EtT would be expected to cause, re-
spectively, G:C -- T:A and T:A -- C:G transition mu-
tations by facilitating mispairing during DNA replica-
tion. Indeed, analysis ofthe types ofmutation induced
following exposure of bacteria to ENU reveal that the
majorityofthechangesaretransitionmutationsofthese
types (47). A low level of transversion mutation was
found, but notably no T:A -- A:T transversions are
detected. T:A-- A:Ttransversionmutationshave, how-
ever, been detected in globin genes of the progeny of
female mice treated with ENU (48,49). To explain how
ENU causes T:A -- A:Tmutations, it may be necessary
to search for new promutagenic lesions from among the
variety ofdifferent products that result from exposure
of DNA to ENU.
c-myc, pvt-1, and pim-1 Loci
B-cell neoplasms (called plasmocytomas) can be in-
duced in BALB/c and NZB mouse strains by intraper-
itoneal injection of either mineral oil or pure alkanes
such as prisane (2,6,10,14-tetramethylpentadecane).
These agents cannot attack DNA directly but induce a
severe inflammatory response at the site of injection,
and plasmocytomas are detected as free cells after at
least 130 days (50). Cytogenetic studies have revealed
that the majority of plasmocytomas possess specific
chromosomal translocations involving chromosomes 15
and 12 or chromosomes 15 and 6. The translocation ob-
served most frequently involves the c-myc locus on
chromosome 15 and the immunoglobin heavy chain
(IgH) locus on chromosome 12; translocations involving
the immunoglobin K light chain on chromsome 6 and a
locus designated pvt-1 on chromosome 15 are found less
frequently. [For a review see Cory (16).]
The immunoglobin heavy chain gene undergoes a se-
ries ofrearrangements during B-cell development. In-
itiallytheregion ofthegeneencodingtheimmunoglobin
variable region is assembled by a series of recombina-
tions involving variable (V), diversity (D), and joining
(J)elements leadingtotheproductionofageneencoding
a ,-class heavy chain. Subsequently, recombination oc-
curs between switch regions (S), leading to the con-
struction ofgenes that determine the synthesis ofother
classes ofimmunoglobin.
The major translocation found in plasmocytomas
brings together the c-myc locus and the 3'-end of the
IgH locus in a "head-to-head" configuration. Within the
IgH locus the switching regions are the predominant
targets for translocation, and it is generally supposed
that translocations result from rare aberrant interchro-
mosomal recombinations that occur during B-cell ma-
turation. Within the c-myc gene, the majority oftrans-
locations occur either 5'-end to the first exon or within
the first exon and intron. In plasmocytomas the un-
rearranged c-myc allele is usually transcriptionally si-
lent while the translocated allele is actively transcribed
(51). This observation indicated that a major conse-
quence of IgH invasion of the c-myc locus is the dere-
gulation of c-myc expression. In fact, it is the consti-
tutive expression ofthe rearranged c-myc locus that is
believed to play a major role in the induction of plas-
mocytomas. In contrast, the precise role that exposure
to mineral oil or pristane plays in generating these
translocations still remains to be established.
AKR mice, in contrast to most other mouse strains,
develop thymomas spontaneously after6months ofage.
AKR mice express high levels of endogenous murine
leukemia viruses (MuLVs), and in some spontaneous
AKR thymomas and in some thymomas induced by in-
fectingyoung mice ofother strains with MuLVs, a crit-
ical event in tumor development involves modification
of cellular c-myc and pim-1 genes by proviral integra-
tion at these loci (52,53). The pim-1 gene was, in fact,
originally isolated as a specific site of integration of
MuLVs inmouse thymomas and is amemberofafamily
ofgenes encoding protein kinases (54).
WhenyoungAKR mice are treated with asingle dose
of MNU, thymomas start to appear at 3 months, and
all ofthe treated mice developed thymomas before the
first tumors appear in untreated groups (55,56). Pro-
viral integrations at the pim-1 and c-myc loci have also
been detected in these MNU-induced thymomas. It is,
however, clear thatthe MNU-induced tumors are quite
distinct from the spontaneous thymomas that develop
in the AKR mouse strain because they lack a class of
recombinant MuLVs (called MCF viruses) that are
foundinallspontaneoustumorsandbecause, incontrast
to spontaneous thymomas, they frequently contain ac-
tivated ras genes (56). In fact, it is possible that the
development of thymomas in MNU-treated AKR mice
involves acooperationbetweengenesthatareactivated
by chemical exposure (e.g., ras) and genes that are
activated by proviral integration (e.g., pim-1 and c-
myc).
Cytogenetic studies have revealed thatchemically in-
duced thymomas exhibittrisomy ofchromosome 15. Al-
though the significance of this abnormality remains to
beestablished, itisconceivablethatthemodestincrease
in copy number ofgenes such as c-myc that are located
inchromosome 15mayfacilitatethymomadevelopment.
The mos Gene
Activated cellular mos genes have been detected in
a small proportion of mineral-oil-induced mouse plas-
mocytomas (57-61). Mos was originally identified as a
transforming sequence of Moloney murine sarcoma vi-
rus and is now believed to encode a cytostatic factor
that is responsible for causing meiotic arrest in verte-
brateeggs(62). Mosisnormallyexpressedathighlevels
in oocytes (63), but inappropriate expression ofmos at
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modest levels in certain other cell types can result in
cell transformation (64).
The altered mos genes found in plasmocytomas were
originally detected as gene rearrangements by South-
ern analysis. More detailed molecular analyses dem-
onstrated that the rearrangements resulted from inte-
gration of intercisternal A-particle (IAP) genomes
within the 5'-end ofthe coding region of the mos gene
(58-60). IAP's particle genomas are located at 1000 or
more sites per haploid genome and are generally con-
sidered to represent a class ofmovable genetic element
that is frequently expressed in many murine tumors,
includingplasmocytomas. Thetranscriptionalactivation
of mos that accompanies IAP integration appears to
resultfromthejuxtaposition ofmos sequencesandtran-
scription control elements present in the LTRs of the
IAP genome and from the separation of mos from cis-
action negative control elements normally located
around 1 kb upstream from the mos coding region
(64,65).
Uncharacterized Transforming
Genes
Although the great majority ofgenes detected using
DNA transfection procedures are members of the ras
gene family, in some studies low frequencies of genes
that are not closely related to H-ras, K-ras, and N-ras
are also observed. For example, analyses of 113 chem-
icallyinduced mousehepatomas revealed that58tumors
contained activated H-ras, 3 tumors transferred acti-
vated K-ras, 2 tumors yielded activated raf, and 3 tu-
mors contained activated genes that were apparently
unrelated to ras or raf(66-68). Similarly, in studies on
DMBA-transformed mouse urothelial cells, 1 of the 4
activated genes that were detected was not a member
of the ras gene family (69). In other studies, higher
incidences of activation of non-ras gene have, appar-
ently, been observed. Thus, examination of4 activated
fibrosarcomas induced in rats by 1,8-dinitropyrene (1,8-
DNP) revealed that 1 tumor contained K-ras, while the
other 3 contained activated genes that were unrelated
to ras (70,71). In addition, McMahon et al. (72) have
provided evidence for transforming gene activation in
a high proportion ofhepatocellular carcinomas induced
in Fischer rats by aflatoxin B1. Activated K-ras was
detected in 2 carcinomas, while evidence that 8 of the
11 tumors contained genes that were unrelated to ras
was also provided.
Garte et al. (73) found that DNA from seven nasal
squamous cell carcinomas that were induced in rats by
inhalation ofmethylmethanesulfonate (MMS) efficiently
transformed NIH 3T3 cells. MMSis an alkylating agent
that produces only low levels of 0-alkylated bases and
would be expected to be only apoor inducerofthe point
mutations that are required for ras gene activation.
Accordingly, the genes detected in the MMS-induced
tumors were not closely related to H-, K-, and N-ras.
Shiner et al. (74) examined the mechanism of mor-
phological transformation ofa stable immortal hamster
cell line (4DH2) followingexposure to MMU, ENU, and
dimethylsulfate (DMS). In these experiments, treat-
ment with ENU and MNU gave rise to both progres-
sively growinglarge foci and compact smallfoci, where-
as treatment with DMS produced almost exclusively
large foci. Since ENU and MNU are both potent point
mutagens, while DMS is only a poor inducer of point
mutations, it was assumed that the small foci arose as
a consequence of point mutagenic events. Similarly,
since each of these three alkylating agents produces
similar levels ofgross chromosome damage, it was pro-
posed that the generation of large foci involved more
substantial genetic alterations and was unlikely to in-
volve ras gene activation. In agreement with this pre-
diction, all ofthe dominanttransforminggenes detected
in large foci using DNA transfection procedures were
not related to K-, N-, or H-ras.
Concluding Remarks
Several distinct types ofgenetic alteration have been
implicated in the activation of non-ras transforming
genes. Forexample, activation ofthe metgene involves
a chromosomal rearrangement, activation of neu re-
quires a point mutation, and activation ofpim-1 and c-
myc in chemically induced thymomas involves proviral
integration. There is also some evidence that gene am-
plification may occur in chemically and radiation-in-
duced tumors. Thus, certaintypesofchemicallyinduced
tumors are known to contain double minute chromo-
somes, the morphologicalhallmarkofgene amplification
(75). In addition, Wong (76) has detected amplification
of the gene encoding the epidermal growth factor re-
ceptor (c-erbB-1) in oral carcinomas induced by treating
hamsters with DMBA, while Sawey et al. (77) observed
amplification of c-myc in radiation-induced mouse skin
tumors.
A potentially exciting area for future investigation is
the analysis of loss or inactivation oftumor-suppressor
genes during chemical carcinogenesis. Since the loss or
inactivation of specific chromosomal loci, such as the
p53 and Rb-1 genes, is a common feature ofthe devel-
opment of many types of human cancer, it would be
useful to have an animal model that would allow the
mechanism ofgene loss and its role in carcinogenesis to
be studied in more detail. It is perhaps worthy of note
that the p53 gene, which is now believed to be a tumor-
suppressor gene, can be overexpressed and mutated in
chemicallytransformed cells. Indeed, p53wasoriginally
identified as both a cellular protein associated with the
large T-antigen of SV40 and as a tumor-specific trans-
plantation antigen in 3-methylcholanthrene-induced
mouse fibrosarcomas (78-81).
Carcinogenesis is generally considered to be a mul-
tistep process. Evidence forthis isprovided by analysis
ofthepathology ofcancerdevelopment (82) andbystud-
ies on the kinetics of appearance of cancer (83). In ad-
dition, it is now well established that transformation of
certain types of primary cell may be activated by co-
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operation between different classes of activated onco-
gene; for example, Land et al. (84) demonstrated that
primary rat fibroblasts can be transformed by cooper-
ation between activated forms of ras and myc. When
considered together, these observations indicate that
several genetic changes may berequired to activate full
transformation. In this regard, the identification ofge-
netic changes that cooperate with, for example, neu
activation in schwannomas or myc activation in plas-
mocytomas, may provide a fruitful area for future stud-
ies.
I thank Helen Anton for typing the manuscript. C. S. C. is sup-
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